SS-31 (30mg Vial)

01 · At a glance

Quickstart Highlights

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane [1] , stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis [2] . This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome [3] . This educational protocol presents a once‑daily subcutaneous approach using the 30 mg vial format with practical reconstitution for insulin‑syringe measurements.

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Approach (3.0 mL = ~10 mg/mL)

5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.

Advanced / Aggressive Approach

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
3. Gently swirl/roll until fully dissolved (clear solution).
4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light; use within 4 weeks.

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Protocol Overview

• Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand [1] [2] .
• Schedule: Daily subcutaneous injections for 8–12 weeks (clinical trials typically 4–12 weeks).
• Dose Range: 5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).
• Reconstitution: 3.0 mL per 30 mg vial (~10 mg/mL) for convenient single‑syringe administration.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Dosing Protocol

• 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.
• Inject once daily subcutaneously at a consistent time. This 30 mg vial reconstituted with 3.0 mL keeps standard doses within a single insulin syringe for convenience and accuracy.
• Advanced dosing (15–20 mg/day) is based on short‑term clinical trial protocols [4] [5] for severe mitochondrial conditions and should only be pursued under medical supervision. Doses above 10 mg require splitting into two separate subcutaneous injections at different sites. Clinical trials have not extensively evaluated SS‑31 beyond 12 weeks; extended use requires careful monitoring.
• If values change, rerun the calculator and update the protocol so future logs match the active plan.

Storage Instructions

• Lyophilized: freeze at −20 °C (−4 °F) ; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) ; use within 4 weeks.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.
• Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.

04 · Good to know

Important Notes

• Practical considerations for consistency, safety, and tolerability.
• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy [14] .
• Inject slowly over several seconds; wait briefly before withdrawing the needle to prevent leakage.
• Mild injection‑site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials [4] [6] ; these typically resolve within hours.
• Document daily dose, injection site, and any adverse reactions to maintain consistency and identify patterns.
• For doses requiring split injections (≥15 mg), space injections at least 2 inches apart on different body regions.

05 · How it works

How This Works

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane [1] , stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis [2] .

This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome [3] .

This educational protocol presents a once‑daily subcutaneous approach using the 30 mg vial format with practical reconstitution for insulin‑syringe measurements.

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

• Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
• Track body metrics only if they are relevant to the user's goal and approved data sources.
• Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

• SS-31 observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
• This section is not a claim of therapeutic benefit.

08 · Technique

Injection Technique

09 · Evidence

References